Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
08/2003
08/27/2003CN1437974A Toxicant-elimination soup of rhizome of Chinese goldthread and new of its active part
08/27/2003CN1437973A Medicinal composition for treating ischemic cerebrovascular accident and preparation method
08/27/2003CN1437965A Ginkgo-leaf small pills
08/27/2003CN1437964A Medicine for treating coronary heart disease
08/27/2003CN1437959A Chinese prepartory for treating cardiovascular and cerebrovascular disease and preparation method
08/27/2003CN1437952A Compound Huanweihuangyangxing D tablet preparation
08/27/2003CN1437950A Herba florigen oral drip-ball and production method
08/27/2003CN1437941A Preparation method for soft capsule of matrine for treating arythmia and acute enteritis
08/27/2003CN1119416C Human interleukin 2 derivatives and human heart sodium medium fusion gene, its protein products and uts thereof
08/27/2003CN1119340C Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
08/27/2003CN1119334C Substsituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of disease charaterized by abnomal cell proliferation
08/27/2003CN1119328C Acylaminoalkenylene-amide derivatives as NK1 and NK2 antagonists
08/27/2003CN1119313C Inhibition of matrix metallo proteases by 2-(omega-aroylalkyc)-4-biaryl-oxobutyric acids
08/27/2003CN1119166C Health beverage for preventing and curing hypertension and hyperlipemia
08/27/2003CN1119145C Liposomal compositions and method of using them
08/26/2003US6610906 Nucleotide sequences for gene regulation and methods of use thereof
08/26/2003US6610890 Treatment and/or prevention of diabetic complications; such as 3,3',4,4',5,5'-hexabromo-2,2'-dihydroxy-oxydiphenyl
08/26/2003US6610842 Removing hydroxyl protecting group from compound of given formula and treating with another compound; wide range of diagnostic and therapeutic uses
08/26/2003US6610829 Human extracellular matrix-1
08/26/2003US6610826 Cyclopeptide derivatives with integrin inhibitor properties
08/26/2003US6610821 Cyclic peptide of given amino acid sequence; can use to improve drug delivery process, inhibit angiogenesis, increase vasopermeability; treatment of autoimmune and inflammatory diseases
08/26/2003US6610820 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
08/26/2003US6610745 Use of 2-hydroxy-4-trifluoromethyl-benzoic acid derivatives as inhibitors of the activation of the nuclear transcription factor NF-KS
08/26/2003US6610744 Methods of treatment with compounds having RARα receptor specific or selective activity
08/26/2003US6610743 Bicyclic metabotropic glutamate receptor ligands
08/26/2003US6610738 Treatment of Alzheimer's Disease by combining both acetylcholinesterase inhibitory activity and antioxidant activity (by virtue of their carbamoyl and flavonoid pharmacophores)
08/26/2003US6610737 Non-psychotropic cannabinoids
08/26/2003US6610725 Fluorinated imidazoline benzodioxane, preparation and therapeutic uses thereof
08/26/2003US6610719 Use of prostaglandin (PGE2) receptor a (EP4) selective agonists for the treatment of acute and chronic renal failure
08/26/2003US6610717 Selectively inhibits action of N-type calcium channel; treatment of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease
08/26/2003US6610716 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging
08/26/2003US6610704 Antithrombotic amides
08/26/2003US6610697 Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-a]pyrimidines, and related pharmaceutical compositions and methods
08/26/2003US6610696 Such as 2-(4-(2-(2-(4-(3,5-dimethyl-isoxazol-4-yl)-phenyl)-5-methyloxazol-4-yl) -ethyoxy)-phenoxy)-2-methylpropionic acid for treatment of diabetes (lowering serum triglycerides)
08/26/2003US6610695 Prophylaxis or treatment of CSBP/RK/p38 kinase mediated disease
08/26/2003US6610691 Carboxylic acid derivatives, their production and use
08/26/2003US6610688 For therapy of blood vessel proliferative disorders; fibrotic disorders; mesangial cell proliferative disorders; metabolic disorders; allergies; asthma; thrombosis; nervous system diseases; and cancer
08/26/2003US6610685 Fused indole derivatives
08/26/2003US6610683 Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
08/26/2003US6610682 Comprising insulin resistance improving agents in combination with drugs selected from angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors with a diluent or carrier
08/26/2003US6610674 Method of treating inflammatory conditions with progesterone analogs
08/26/2003US6610624 Method for enhancing catalytic activity with supercritical fluids
08/26/2003US6610534 Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases
08/26/2003US6610523 Human mitogen-activated (MAP) kinase kinase isoforms (MKKs). MKKs mediate unique signal transduction pathways that activate human MAP kinases p38 and JNK, which result in activation of other factors, including activating
08/26/2003US6610480 Identification of genes which are differentially expressed in hypertrophic cardiac tissue as compared to normal cardiac tissue. Accordingly, the present invention provides nucleotide sequences of genes and promotion or inhibition of the function
08/26/2003US6610320 Mixture of cocoa plant extract and antichloesterol agent
08/26/2003US6610283 Poly(diallylamine)-based bile acid sequestrants
08/26/2003CA2092211C Imidazole compounds, their preparation and use
08/23/2003CA2473075A1 Process for the manufacture of hmg-coa reductase inhibitory mevalonic acid derivatives
08/21/2003WO2003069346A2 Diagnostic method for stroke
08/21/2003WO2003069302A2 Alpha-substituted arylalkyl phosphonate derivatives
08/21/2003WO2003068959A1 Novel screening method
08/21/2003WO2003068937A2 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
08/21/2003WO2003068813A2 Group b streptococcus antigen
08/21/2003WO2003068811A2 Cytotoxic t-cell epitopes from chlamydia
08/21/2003WO2003068803A2 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
08/21/2003WO2003068776A1 [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
08/21/2003WO2003068760A2 Compounds possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders
08/21/2003WO2003068759A1 Piperazine derivatives as anti-inflammatory agents
08/21/2003WO2003068757A1 Novel pyridin- and pyrimidin-derivatives
08/21/2003WO2003068754A1 Therapeutic substituted indazole derivatives
08/21/2003WO2003068750A1 Jnk inhibitor
08/21/2003WO2003068748A1 Novel pyridine- and quinoline-derivatives
08/21/2003WO2003068747A1 Nicotinamide derivates useful as p38 inhibitors
08/21/2003WO2003068746A1 Aryl ureas as kinase inhibitors
08/21/2003WO2003068743A1 Chemical compounds
08/21/2003WO2003068725A2 Process for the preparation of 4-hetero-substituted phenylalanine derivatives
08/21/2003WO2003068270A1 Method of radio-labelling biomolecules
08/21/2003WO2003068263A1 Remedy for hypertension
08/21/2003WO2003068240A1 Alpha-substituted heteroarylalkyl phosphonate derivattives
08/21/2003WO2003068237A1 Beta-sheet mimetics and composition and methods relating thereto
08/21/2003WO2003068235A1 Nicotinamide derivatives useful as pde4 inhibitors
08/21/2003WO2003068234A1 Nicotinamide derivatives and a tiotropium salt in combination for the treatment of e.g. inflammatory, allergic and respiratory diseases
08/21/2003WO2003068232A1 Nicotinamide derivatives useful as pde4 inhibitors
08/21/2003WO2003068230A1 Substituted pyridinones as modulators of p38 map kinase
08/21/2003WO2003068228A1 Aryl ureas with angiogenesis inhibiting activity
08/21/2003WO2003068226A1 2-oxazolamines and their use as 5-ht2b receptor antagonists
08/21/2003WO2003068224A2 Use of inhibitors of the sodium-dependent chloride-bicarbonate-exchanger for treating thrombotic and inflammatory diseases
08/21/2003WO2003068216A1 The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure
08/21/2003WO2003068212A1 Use of sodium/hydrogen exchange inhibitors from the treatment of thrombotic and inflammatory diseases
08/21/2003WO2003068208A1 Methods of reducing angiogenesis
08/21/2003WO2003068202A1 Compositions comprising lycopene for the treatment and prevention of angiogenesis associated pathologies
08/21/2003WO2003068199A1 Use of extracts containing phytoestrogen selectively modulating estrogen-receptor-beta
08/21/2003WO2003068197A1 Method for systemic drug delivery through the nail
08/21/2003WO2003068193A1 Pharmaceutical composition comprising n- ((1-n-butyl-4-piperidinyl) methyl)-3, 4-dihydro-2h- (1, 3) oxazino (3, 2-a) indole-10-carboxamide or salt and process therefor comprising dry granulation
08/21/2003WO2003068171A2 Method and composition for treatment of inflammation and aids-associated neurological disorders
08/21/2003WO2003068166A2 Treatment of ophthalmic disorders using urea and urea derivatives
08/21/2003WO2003068153A2 CARDIAC-SPECIFIC 11β HYDROXYSTEROID DEHYDROGENASE TYPE 2 TRANSGENIC MICE
08/21/2003WO2003068140A2 Novel pyridazine derivatives, use of the same as medicaments, pharmaceutical compositions and method for producing the same
08/21/2003WO2003067991A1 Compositions and methods for treatment of microbial infections
08/21/2003WO2003067979A1 Drugs to be used in organ transplantation
08/21/2003WO2003055913A3 Secreted protein
08/21/2003WO2003027075A3 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
08/21/2003WO2003007930A3 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
08/21/2003WO2003006070A3 Improved chelator conjugates
08/21/2003WO2003004006A8 Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
08/21/2003WO2002100847A3 Factor xa inhibitor
08/21/2003WO2002088664A3 Control of compactability through crystallization
08/21/2003WO2002085384A3 Lubricious coatings for substrates
08/21/2003WO2002067861A3 Oncolytic adenoviral vectors
1 ... 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 ... 1595